---
title: Therapeutic potential and research on psychedelics
videoId: fpwDi8f6TLQ
---

From: [[⁨cleoabram⁩]] <br/> 

Psychedelics are a broad category of drugs, encompassing substances often known by names such as ecstasy, acid, molly, and magic mushrooms <a class="yt-timestamp" data-t="00:02:27">[00:02:27]</a>. The term "psychedelic" originates from Greek words meaning "mind manifesting" <a class="yt-timestamp" data-t="00:03:11">[00:03:11]</a>. When taken, these drugs can induce vivid sensory experiences, such as seeing colors or shapes, and can also bring about intense emotions, profoundly altering one's perception of the world and self <a class="yt-timestamp" data-t="00:03:15">[00:03:15]</a>.

## Historical Context of Research

The history of [[history_and_legal_status_of_psychedelics | psychedelics and their legal status]] has significantly impacted research into their therapeutic potential.

### Early Research (Pre-1980s)
In 1955, [[history_and_legal_status_of_psychedelics | psychedelics]] were legal in both the UK and the US and were considered an exciting area of medical research <a class="yt-timestamp" data-t="00:00:40">[00:00:40]</a>. Historically, substances like psilocybin mushrooms and peyote (containing mescaline) were used in religious rituals by ancient civilizations like the Maya and Aztec, and continue to be part of some modern religious ceremonies <a class="yt-timestamp" data-t="00:04:24">[00:04:24]</a>. In the early 1900s, [[history_and_legal_status_of_psychedelics | psychedelics]] like LSD were legal and distributed to doctors for experimental use <a class="yt-timestamp" data-t="00:04:34">[00:04:34]</a>.

### The Impact of the [[public_perception_and_the_war_on_drugs | War on Drugs]]
By the 1980s, the landscape changed dramatically with the declaration of the "[[public_perception_and_the_war_on_drugs | War on Drugs]]" in the United States <a class="yt-timestamp" data-t="00:00:50">[00:00:50]</a>, leading to the banning of [[history_and_legal_status_of_psychedelics | psychedelics]] and a significant shift in research <a class="yt-timestamp" data-t="00:00:56">[00:00:56]</a>. The conclusion that these drugs were too dangerous for human research was primarily a socio-political phenomenon, driven by their association with counter-culture movements <a class="yt-timestamp" data-t="00:05:31">[00:05:31]</a>.

During this period, research that *did* occur often supported the government's narrative of extreme danger, shaping [[public_perception_and_the_war_on_drugs | public opinion]] <a class="yt-timestamp" data-t="00:05:49">[00:05:49]</a>. A notable example is a 2002 Johns Hopkins study on ecstasy's effects on monkey brains, which controversially reported permanent brain damage and a 20% mortality rate <a class="yt-timestamp" data-t="00:06:03">[00:06:03]</a>. This study was later retracted when researchers discovered they had accidentally injected the monkeys with methamphetamine instead of ecstasy, yet the damage to the [[public_perception_and_the_war_on_drugs | public understanding]] of [[psychedelics_and_their_effects_on_the_brain | psychedelics]] had already been done <a class="yt-timestamp" data-t="00:06:49">[00:06:49]</a>.

### Modern Resurgence in Research
The past decade has seen a significant revitalization of research into [[psychedelics_and_their_effects_on_the_brain | psychedelics]] <a class="yt-timestamp" data-t="00:07:28">[00:07:28]</a>. This new wave of research has generated considerable interest and hope for their potential in treating various conditions <a class="yt-timestamp" data-t="00:07:32">[00:07:32]</a>.

Dr. Matthew Johnson, a professor of Psychiatry and Behavioral Sciences at Johns Hopkins, is a leading researcher in this field, studying both the mechanisms and potential therapeutic applications of [[psychedelics_and_their_effects_on_the_brain | psychedelics]] since 2004 <a class="yt-timestamp" data-t="00:03:47">[00:03:47]</a>.

## Therapeutic Applications

Current research suggests that [[psychedelics_and_their_effects_on_the_brain | psychedelics]] could offer significant health benefits and potentially treat disorders affecting millions of people <a class="yt-timestamp" data-t="00:01:24">[00:01:24]</a>.

Specific areas of promising research include:
*   **Psilocybin:** A high dose of psilocybin has been shown to relieve anxiety and depression in cancer patients for up to six months <a class="yt-timestamp" data-t="00:07:46">[00:07:46]</a>. It is also being investigated for alcoholism, smoking cessation, cancer-related distress, and major depressive disorder <a class="yt-timestamp" data-t="00:08:24">[00:08:24]</a>.
*   **MDMA:** Two-thirds of patients treated with MDMA no longer experienced PTSD in one study <a class="yt-timestamp" data-t="00:07:54">[00:07:54]</a>. MDMA in the treatment of PTSD is one of the most confident areas of research <a class="yt-timestamp" data-t="00:08:19">[00:08:19]</a>.

### Mechanism of Action
[[psychedelics_and_their_effects_on_the_brain | Psychedelics]] (specifically classic psychedelics) act on the serotonin 2A receptor in the brain <a class="yt-timestamp" data-t="00:02:57">[00:02:57]</a>. MDMA and ketamine, while generally classified under [[psychedelics_and_their_effects_on_the_brain | psychedelics]], work in slightly different ways <a class="yt-timestamp" data-t="00:03:03">[00:03:03]</a>.

Researchers believe that [[psychedelics_and_their_effects_on_the_brain | these drugs]] can alter communication between individual brain cells, allowing them to form new connections <a class="yt-timestamp" data-t="00:08:43">[00:08:43]</a>. This "rewiring" of the brain could change how emotions and desires are processed, even after the drug's effects have worn off <a class="yt-timestamp" data-t="00:09:11">[00:09:11]</a>. This ability to "blast people out of those ruts" of narrowed mental and behavioral repertoires is why they might help with a range of disorders <a class="yt-timestamp" data-t="00:08:51">[00:08:51]</a>.

### Limitations and Risks
It is crucial to acknowledge that [[psychedelics_and_their_effects_on_the_brain | psychedelics]] are not suitable for everyone <a class="yt-timestamp" data-t="00:09:21">[00:09:21]</a>. For individuals with a family history of schizophrenia, research indicates that [[psychedelics_and_their_effects_on_the_brain | psychedelics]] could trigger manic or psychotic episodes <a class="yt-timestamp" data-t="00:09:26">[00:09:26]</a>. It is important to avoid over-hyping science that is still in progress <a class="yt-timestamp" data-t="00:09:31">[00:09:31]</a>.

## [[future_of_psychedelic_legalization_and_regulation | Future of Legalization and Regulation]]

The promising research has led to a growing debate about the [[future_of_psychedelic_legalization_and_regulation | legalization of psychedelics]] <a class="yt-timestamp" data-t="00:01:17">[00:01:17]</a>. Some of these drugs are now on the path to FDA approval <a class="yt-timestamp" data-t="00:10:19">[00:10:19]</a>.

Dr. Matthew Johnson anticipates MDMA could be FDA-approved for PTSD in the US within a year or two, followed by psilocybin a year or two after that <a class="yt-timestamp" data-t="00:10:24">[00:10:24]</a>.

The most likely initial path for [[future_of_psychedelic_legalization_and_regulation | legalization]] is not recreational sale like cannabis, but rather supervised therapeutic use <a class="yt-timestamp" data-t="00:10:40">[00:10:40]</a>. This model would involve:
*   **Prescription by a Doctor:** MDMA and psilocybin would be prescribed by a medical doctor <a class="yt-timestamp" data-t="00:11:15">[00:11:15]</a>.
*   **Supervised Setting:** The "trip" would be supervised by a licensed therapist or facilitator in a certified clinic <a class="yt-timestamp" data-t="00:11:21">[00:11:21]</a>.
*   **Therapeutic Integration:** This process would involve a comfortable environment, often with music and an eye mask, with the professional ensuring patient safety and comfort during this vulnerable experience <a class="yt-timestamp" data-t="00:11:26">[00:11:26]</a>. Research is ongoing to determine the most effective types of therapy and stimulation during these sessions <a class="yt-timestamp" data-t="00:11:49">[00:11:49]</a>.

Some states, like Oregon and Colorado, have legalized supervised psilocybin use in "healing centers" with a facilitator (not necessarily a doctor), though these centers are not yet open <a class="yt-timestamp" data-t="00:12:03">[00:12:03]</a>. Currently, the vision for taking [[psychedelics_and_their_effects_on_the_brain | psychedelics]] in a legal setting is exclusively supervised <a class="yt-timestamp" data-t="00:12:23">[00:12:23]</a>.

The goal moving forward is to base regulation on robust scientific evidence, avoiding unwarranted fear or hype, to ensure that these potential treatments can help the millions of people struggling with health conditions <a class="yt-timestamp" data-t="00:12:42">[00:12:42]</a>.